ProQR Therapeutics (PRQR) Minority Interest (2017 - 2023)

ProQR Therapeutics (PRQR) has reported Minority Interest for 7 consecutive years, with -$330006.7 the latest figure, recorded in Q2 2023.

• Quarterly Minority Interest rose 26.58% year-over-year to -$330006.7 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was -$330006.7 (up 26.58% YoY) and the FY2022 annual result came in at -$436974.4, up 36.42% from the prior year.
• Minority Interest climbed to -$330006.7 in Q2 2023 per PRQR's latest filing, from -$348214.0 in the prior quarter.
• Over the last five years, Minority Interest for PRQR reached as high as -$360.73 in Q1 2019 and fell as low as -$696428.0 in Q1 2022.
• A 5-year average of -$479955.8 and a median of -$539390.3 in 2019 frame the typical range for Minority Interest.
• Annual changes were most pronounced in 2019 — Minority Interest tumbled 215552.17% — and 2021, when it soared 99.89%.
• Year by year, Minority Interest stood at -$564425.3 in 2019, then retreated by 9.88% to -$620185.1 in 2020, then slipped by 10.83% to -$687324.4 in 2021, then jumped by 36.42% to -$436974.4 in 2022, then climbed by 24.48% to -$330006.7 in 2023.
• According to Business Quant data, Minority Interest over the past three periods registered -$330006.7, -$348214.0, and -$436974.4 for Q2 2023, Q1 2023, and Q4 2022 respectively.